Several articles focus on new achievements made by scientists in the field of melatonin research in recent years!

This article has compiled several important research results to focus on the new advances scientists have made in melatonin research in recent years and share them with you! Photo credit: NCI/NIH1 JPR: New Discovery! Melatonin may be expected to help enhance brain memory! Doi:10.1111/jpi.12703 Walk up to the shelves of your local pharmacy and you'll find fish oil, ginkgo, vitamin E and ginseng, all touted as memory enhancers that can help prevent cognitive decline in the body, and you'll find that melatonin is often sold in the U.S. as a sleep supplement, and now it seems that melatonin salespeoes may need to rethink their use.
In a recent study published in the international journal Journal of Pineal Research, scientists from Tokyo Medical and Dental University and others found that melatonin and its two metabolites may help the body's memory stay in the brain and may protect mice and humans from cognitive decline in the brain.
one of the easiest ways to test a mouse's memory is to rely on its natural tendency to examine unfamiliar objects, and if so, mice spend more time examining unfamiliar objects than familiar ones.
trick is to remember something if you want it to become familiar.
like humans, mice's cognitive decline was mainly due to poor memory, and when they were tested for cognitive tasks on new things, they behaved as if both objects were new.
researchers are curious about melatonin metabolites, the molecules that break down when they enter the body, and researcher Attori explains that we all know that melatonin can be converted into N1-acetyl-N2-methyl-methoxygenide (AFMK) in the brain. And N1-acetyl-5-methyl canine urine amine (AMK) molecules, which may promote brain cognition, were tested by researchers who familiarized mice with objects and injected them with a dose of melatonin and two metabolites an hour later.
The researchers then tested the memory of the mice the next day and found that the mice's body's memory improved after treatment, and that AMK was the most effective, with three substances accumulating in the brain's hema body, an area that is important for converting body experience into memory.
: JPR: Heavy! Scientists hope to treat breast cancer with the circadian rhythm hormone melatonin! Doi:10.1111/jpi.12693 In a recent study published in the international journal Journal of Pineal Research, scientists from Brazil and the United States used the study to describe a group of genes that are potentially regulated by melatonin in certain cancer types, especially breast cancer, and the results may be used to help develop new, individualized therapies for the treatment of diseases.
type of tumor appears to be directly related to levels of melatonin produced by cells, and understanding the mechanisms at which the hormone affects molecular signals at genetic levels may help scientists develop individual therapies based on melatonin, said luiz Gustavo Chuffa, a researcher at the University of Hong Kong.
Melatonin is commonly known as "sleep hormone" because its function includes regulating the body's wake cycle, and in laboratory trials, researchers have found that melatonin has anti-tumor properties;
the majority of tumor cells have lower levels of melatonin, but laboratory tests have shown that melatonin therapy can increase tumor cell death and reduce tumor cell proliferation, which is important to avoid tumor progression and metastasis.
Now that researchers are conducting clinical trials to assess whether melatonin can be used to treat cancer, researchers have developed special treatments for different breast cancer subsypes, some of which may respond better to melatonin-based alternative therapies, while others may not.
: PLoS Biol: New Discoveries! Melatonin may be expected to help treat COVID-19! Doi:10.1371/journal.pbio.3000970 In a recent study published in the international journal PLoS Biology, scientists from institutions such as the Cleveland Clinic found that melatonin may be available as a new treatment for COVID-19, a hormone molecule that regulates the body's wake-up cycle and is often used as a non-prescription sleeping pill.
With the coVID-19 epidemic spreading around the world, redirecting FDA-approved drugs for treatment may still be the most effective and cost-effective way to treat or prevent the disease, researchers have developed a new artificial intelligence platform to help identify potential drugs that could treat COVID-19, and researchers have found that melatonin may be a potential candidate for COVID-19.
analyzed data on COVID-19 patients registered with the Cleveland Clinic, the researchers said that when age, race, smoking history, and multiple disease complications were adjusted, participants were about 30 percent less likely to test positive for SARS-CoV-2, notably an increase in the likelihood of testing positive for the virus from 30 percent to 52 percent for African-Americans.
: Melatonin may be a target for a new type of treatment for multiple sclerosis doi:10.1016/j.cell.2015.08.025 In a research paper published in the international journal Cell, from Bregan Women's Hospital The researchers found that seasonal sudden outbreaks in patients with multiple sclerosis may have been directly triggered by lower levels of melatonin in the body in spring and summer, and that studies may help shed light on why patients with autoimmune diseases have a significantly lower risk of recurrence in autumn and winter because of higher levels of melatonin in the body in autumn and winter and lower levels in spring and summer.
Researchers say melatonin therapy may improve clinical symptoms in mouse models with multiple sclerosis by restoring a healthy balance of T lymphocytes in the body, and the results may help develop new treatments for multiple autoimmune disorders.
Francisco J. Quintanta says multiple sclerosis is a neurological disorder that is thought to be caused by T-cells destroying myelin, a substance that envelines nerve cells and protects them, slowing or blocking the flow of information between the brain and the body, triggering symptoms such as visual impairment, muscle weakness, difficulty coordinating and balancing, thinking and memory problems.
( 5) JAMA: Reduced melatonin production is associated with a higher risk of developing type 2 diabetes Doi:10.1001/jama.2013.2710, a study in the international journal JAMA revealed that previous evidence suggests that melatonin may play a role in glucose metabolism, and researchers found a separate correlation between reduced melatonin secretion and an increased risk of type 2 diabetes.
In the background to the article: "Melatonin-like bodies are found in many tissues in the body, including islet cells, reflecting the widespread effects of melatonin on physiological functions such as energy metabolism and weight regulation.
the loss of function of melatonin's remnants is associated with insulin resistance and type 2 diabetes.
, a cross-sectional analysis of non-diabetic patients showed that lower levels of melatonin secreted at night were associated with increased insulin resistance.
" a forward-looking association between melatonin secretion and type 2 diabetes has not been reported in the past.
study was conducted by Ciaran J. McMullan, M.D., and colleagues at Brigham and Women's Hospital in Boston to investigate the relationship between melatonin secretion and the incidence of type 2 diabetes.
this analysis was made up of case-control studies in the Nurses Health Research Group.
among participants without diabetes -- who provided baseline urine and blood samples in 2000 -- the researchers identified 370 women with type 2 diabetes between 2000 and 2012 and 370 controls who matched them.
statistical analysis used to determine the correlation between baseline melatonin secretion and the incidence of type 2 diabetes includes the qualification of demographic characteristics, lifestyle habits, sleep quality test results, and biomarkers of inflammation and endothyl dysfunction.
: Sleep: Melatonin supplements reduce the side effects of β-subject blockers affecting sleep doi:10.5665/sleep.2122 More than 200,000 people in the United States take β-blockers, β-blockers are commonly used drugs to treat cardiovascular disease, anxiety, and high blood pressure.
many of these patients have sleep problems, which may be caused by side effects of β-blockers, which inhibit nighttime melatonin production.
recently, researchers at Brigham and Women's Hospital (BWH) found that melatonin supplements significantly improved sleep quality in patients with β-blocker hypertension.
The study, to be published in the journal Sleep, suggests a link between β-subject blockers and sleep disorders, but so far no clinically relevant studies have tested whether melatonin supplements can improve sleep in these patients.
BWH associate neuroscientist Dr Frank Scheer explained: 'We found that melatonin supplements significantly improved sleep.
the team analyzed 16 patients β high blood pressure who regularly took a 10-blocker blocker to treat high blood pressure.
study participants were given melatonin or a placebo supplement each night before going to bed.
to avoid human factors affecting the results, the trial used a double-blind approach, in which participants and researchers did not know what medication the patient was taking.
:JPR: Melatonin-like MT2 gene polymorphism is closely related to rizhao doi:10.1111/j.1600-079X.2009.00736.x Melatonin pathway is one of the main pathways of biological rhythm signal transducement, affected by the environmental day/night cycle.
natural selection of different solar hours and corresponding circadian rhythms around the world is likely to play an important role in the genetic polymorphism of melatonin pathogens.
Under the joint guidance of Zhang Yaping of the Kunming Institute of Zoology of the Chinese Academy of Sciences and Professor Deng Liangsheng of Chinese University in Hong Kong, phD student Ji Lindan and other researchers systematically analyzed the correlation between melatonin pathogen polymorphism and the length of daylight in the world population (CEPH-HGDP).
study suggests that polymorphism of the melatonin-like MT2 (MTNR1B) gene is closely related to rizhao in populations around the world, and the results have also been validated in Chinese populations.
, melatonin pathogens, especially the genetic polymorphism of MT2 receptors, are likely to experience natural choices of sun.
In addition, the genetic polymorphism was found to be associated with the onset of adolescent idiopathic scoliosis (AIS) in a previous collaboration with Hong Kong's Chinese University, and a recently reported genome-wide study (GWAS) suggests it is a susceptible point for type 2 diabetes.
() more exciting inventory! Stay tuned! 。